Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Posts Flat Revenues, Widened Net Loss in Q3

NEW YORK, Nov. 1 - Caliper Technologies reported flat third-quarter revenue atop increased R&D spending and a slight jump in net loss.

 

For the period ended Sept. 30, total revenue was $6.6 million, largely unchanged from the same quarter one year ago, Caliper said. Broken down, revenue from product sales during the quarter increased to $2.3 million from $1.6 million last year, while receipts from licensing fees fell to $2.4 million from $3.0 million.

 

Third-quarter R&D spending increased to $10.9 million from just under $10 million year over year as total costs and expenses in the period inched up to $17.4 million from $17.2 million.

 

Consequently, net loss in the third quarter went up to $9.4 million, or $.38 per share, from $8.4 million, or $.35 per share, last year, according to Caliper.

 

The company said it had roughly $126.4 million in cash, cash equivalents, and short-term marketable securities as of Sept. 30.

 

Click here for more information.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.